Glenmark Pharma: USFDA approves Abiraterone Acetate Tablets USP

Glenmark  Pharma has received approval from the United States Food & Drug Administration (USFDA) for Abiraterone Acetate Tablets USP, 250 mg. The drug is a generic version of Zytiga tablet sold by Janssen Biotech. 
  
The drug is an androgen synthesis inhibitor indicated for the treatment of prostate cancer. Zytiga Tablets' sales data for the US market for the one-year period was approximately $1.3 billion, as of November 2018.

Glenmark’s current portfolio consists of more than 140 products which are authorized for sale in the US market, while further 54 ANDA’s are pending for approval with the USFDA. In addition to this, Glenmark continues to develop market participation to increase the growth rate of its existing as well as future products. 
  

On Wednesday, at 2:05 pm, the stock was trading 1 per cent lower than its previous close at Rs. 649 per share. The benchmark index BSE Sensex showed volatility and was down 10 points at 36,434.